Cancer BiologybioRxiv
Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development
R. M. Hurley, C. D. McGehee, K. Nesic…·S. H. Kaufmann
This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.
DOI 10.1093/narcan/zcab028